Indication

For the prophylaxis of migraine in adults who have at least four migraine days per month.

Medicine details

Medicine name:
fremanezumab (Ajovy)
SMC ID:
SMC2226
Pharmaceutical company
Teva UK Limited
BNF chapter
Central nervous system
Submission type
Full
Status
Publication due date:
13 January 2020
SMC meeting date:
03 December 2019
Patient group submission deadline:
04 November 2019